Pharmacology · Antibacterial Agents

Drug Interactions, Adverse Effects & Special Populations

Key interactions, class toxicities, dose adjustment, and antibiotic safety in pregnancy and pediatrics

Erythromycin and clarithromycin are potent mechanism-based CYP3A4 inhibitors — they can cause rhabdomyolysis when combined with simvastatin or lovastatin (contraindicated), and raise levels of calcineurin inhibitors, benzodiazepines, and warfarin; azithromycin is a much safer choice in polypharmacy patients.
Rifampin is the most potent CYP inducer in clinical use — it reduces levels of oral contraceptives, warfarin, antiretrovirals, and calcineurin inhibitors; induction persists for 1–2 weeks after stopping and clinicians must plan for the offset effect.
Tetracyclines, fluoroquinolones, and aminoglycosides are contraindicated in pregnancy — tetracyclines cause bone and tooth dysplasia, fluoroquinolones cause arthropathy, and aminoglycosides (especially streptomycin) cause fetal ototoxicity.
Neonates have immature CYP3A4 (~30% of adult activity at birth) and immature renal elimination — standard adult dosing produces toxic accumulation; chloramphenicol gray baby syndrome and aminoglycoside accumulation are direct consequences.
Ceftriaxone is the only antibiotic that does not require renal dose adjustment — its ~40% biliary elimination makes it uniquely useful for serious gram-negative infections in patients with acute kidney injury.

Abbreviations: CYP = cytochrome P450 · QTc = corrected QT interval · MAO = monoamine oxidase · SSRI = selective serotonin reuptake inhibitor · SNRI = serotonin-norepinephrine reuptake inhibitor · TCA = tricyclic antidepressant · CrCl = creatinine clearance · RID = relative infant dose · G6PD = glucose-6-phosphate dehydrogenase · TMP-SMX = trimethoprim-sulfamethoxazole · TDM = therapeutic drug monitoring · AKI = acute kidney injury

Drug Interactions

CYP Interactions

Macrolides (Inhibition) and Rifampin (Induction)

Macrolides — CYP3A4 Inhibition

Erythromycin and clarithromycin: potent mechanism-based (irreversible) CYP3A4 inhibition
↑ Simvastatin and lovastatin → rhabdomyolysis — contraindicated combination
↑ Calcineurin inhibitors (cyclosporine, tacrolimus) → nephrotoxicity and organ rejection risk
↑ Warfarin (via CYP2C9 as well) → bleeding; monitor INR
Azithromycin: much weaker CYP inhibitor — preferred in polypharmacy patients

Rifampin — Potent CYP Induction

Induces CYP3A4, CYP2C9, CYP2C19, P-glycoprotein — broadest induction profile of any antibiotic
↓ Oral contraceptives → contraceptive failure; use barrier method
↓ Warfarin, antiretrovirals (PIs, NNRTIs), calcineurin inhibitors, methadone, antifungals
Induction onset: 1–2 weeks; offset: 1–2 weeks after stopping — plan for both

Other Key Interactions

QTc Prolongation, Serotonin Syndrome, and Additive Toxicity

QTc Prolongation

Risk ranking: moxifloxacin > levofloxacin > ciprofloxacin; azithromycin and clarithromycin also prolong QTc
Check baseline QTc and electrolytes (K⁺, Mg²⁺) before prescribing; avoid if QTc >500 ms
Additive risk with antiarrhythmics, antipsychotics, ondansetron — avoid combinations

Serotonin Syndrome (Linezolid)

Linezolid = reversible nonselective MAO inhibitor — avoid with SSRIs, SNRIs, TCAs, tramadol, meperidine
Triad: mental status changes + autonomic instability + neuromuscular excitability

Additive Toxicity

Aminoglycosides + loop diuretics → synergistic ototoxicity
Vancomycin + piperacillin-tazobactam → significantly higher AKI risk vs. vancomycin + cefepime
Tetracyclines + beta-lactams → pharmacodynamic antagonism (bacteriostatic vs. bactericidal)
Daptomycin + statins → additive myopathy; suspend statins during daptomycin therapy

Major Adverse Effects by Class

Class	Key Toxicity	Clinical Points
Beta-Lactams	Hypersensitivity (IgE-mediated anaphylaxis rare)	True cross-reactivity penicillin-cephalosporin ~1–2% (not 10%); cefazolin lowest risk; skin test-negative patients can receive penicillins; red man syndrome (vancomycin) is NOT allergy
Aminoglycosides	Nephrotoxicity; ototoxicity (cumulative, irreversible cochlear and vestibular)	Extended-interval dosing reduces nephrotoxicity; AUC/MIC-guided TDM; audiometric monitoring if course >14 days; A1555G mitochondrial variant → severe loss after single dose
Fluoroquinolones	Tendinopathy/rupture; peripheral neuropathy; CNS effects; QTc prolongation; aortic aneurysm	Five FDA black box warning categories; contraindicated in myasthenia gravis; restrict to infections where no safer alternative exists; aortic aneurysm risk (2018 warning)
Tetracyclines	Photosensitivity; esophageal ulceration; dental and bone effects	Take with full glass of water; remain upright 30 minutes; doxycycline allowed in children <8 for RMSF (short courses); avoid in pregnancy throughout
Vancomycin	Nephrotoxicity (exposure-dependent); red man syndrome (rate-dependent)	AUC-guided TDM (target AUC/MIC 400–600); infuse over ≥60 min; red man syndrome is NOT allergy — prevented by slow infusion + diphenhydramine; van + pip-tazo → increased AKI
Daptomycin	Myopathy/CPK elevation; eosinophilic pneumonia (rare)	Weekly CPK monitoring; suspend statins; NEVER use for pneumonia — pulmonary surfactant inactivates drug; monitor for paradoxical pulmonary deterioration

Renal and Hepatic Dose Adjustment

Renal Impairment

Key Adjustments by Agent

Most antibiotics: dose-reduce or extend interval as CrCl falls — use Cockcroft-Gault for dosing (not eGFR)
Ceftriaxone: no renal adjustment (biliary elimination ~40%) — preferred for gram-negative infections in AKI
Imipenem: reduce dose when CrCl <70 mL/min — seizure risk with accumulation
Aminoglycosides: switch from extended-interval to TDM-guided at low CrCl; extended intervals become inappropriate
Nitrofurantoin: avoid if CrCl <30 mL/min — inadequate urinary levels + toxic metabolite accumulation
Augmented renal clearance (CrCl >130 mL/min): standard doses may be subtherapeutic — common in ICU patients on aggressive fluids
Nafcillin, moxifloxacin, clindamycin: no renal dose adjustment (hepatic elimination)

Hepatic Impairment

Agents Requiring Adjustment

Metronidazole: reduce dose in severe hepatic impairment; avoid prolonged courses
Clindamycin: reduce in severe impairment (hepatic first-pass metabolism)
Chloramphenicol: immature glucuronidation in neonates → accumulation → gray baby syndrome; reduce in hepatic disease
Rifampin: hepatotoxic — monitor liver function tests; contraindicated in acute hepatic failure
Macrolides: use caution in significant liver disease; erythromycin estolate contraindicated (cholestatic hepatitis risk)
Tigecycline: reduce dose in severe hepatic impairment (Child-Pugh C)
Most beta-lactams, aminoglycosides: primarily renally eliminated — no hepatic adjustment generally needed

Pregnancy and Pediatrics

Pregnancy Safety

Safe, Avoid, and Contraindicated

Safe Throughout Pregnancy

Penicillins, cephalosporins, carbapenems, aztreonam — all beta-lactams generally safe
Erythromycin base, azithromycin, clindamycin

Avoid in First Trimester

TMP-SMX — folate antagonism; risk of neural tube defects in first trimester

Avoid at Term / Near Delivery

TMP-SMX at term → kernicterus (sulfonamide displaces bilirubin from albumin in neonate)
Nitrofurantoin at term → hemolytic anemia in G6PD-deficient neonates

Contraindicated Throughout Pregnancy

Tetracyclines — permanent yellow-brown tooth discoloration and enamel hypoplasia; bone dysplasia
Fluoroquinolones — cartilage and arthropathy concerns in developing musculoskeletal system
Aminoglycosides — fetal ototoxicity; streptomycin has highest documented fetal risk

Pediatrics and Lactation

Neonatal Pharmacokinetics and Breastfeeding

Neonatal Pharmacokinetic Immaturity

Immature CYP3A4 (~30% adult activity at birth; reaches adult levels by 6–12 months) — drugs metabolized by CYP3A4 accumulate
Immature renal GFR and tubular secretion — renally eliminated drugs accumulate; aminoglycosides require extended intervals
Chloramphenicol: immature UDP-glucuronosyltransferase → accumulation → gray baby syndrome (cardiovascular collapse)
Fluoroquinolones: restrict in children — arthropathy in weight-bearing joints; exception for anthrax or specific MDR infections
Tetracyclines: avoid in children under 8 (dental staining, bone effects); doxycycline exception for RMSF

Breastfeeding Safety (RID <10% = generally compatible)

Beta-lactams: RID <1% — fully compatible with breastfeeding
Tetracyclines: chelated by milk calcium — systemic absorption in infant minimal; short courses acceptable
Metronidazole: RID typically <10% — generally compatible; delay feeding 2 hours after single high dose
Fluoroquinolones: avoid during breastfeeding — arthropathy risk in nursing infant uncertain

Chapter 35 Complete — Antibacterial Agents: Cross-Module Themes

Three organizing principles unify all 12 modules. First, mechanism determines toxicity: drugs that inhibit mitochondrial protein synthesis (chloramphenicol, linezolid) cause bone marrow suppression; drugs that inhibit cell wall synthesis in the kidney (aminoglycosides, vancomycin) accumulate in proximal tubular cells and cause nephrotoxicity; drugs that inhibit microtubule and collagen synthesis (fluoroquinolones) damage tendons and cartilage.

Second, pharmacokinetics determine dose adjustment: renal elimination → reduce dose in renal impairment; hepatic elimination (nafcillin, moxifloxacin, clindamycin) → no renal adjustment; immature neonatal enzyme systems → accumulation and organ-specific toxicity at standard doses. Ceftriaxone is the most important exception — dual biliary-renal elimination makes it the only antibiotic that requires no renal dose adjustment.

Third, resistance mechanisms predict which agents fail: ESBL-producing organisms → carbapenems (not pip-tazo for bacteremia); MRSA → agents that bind PBP2a (ceftaroline) or bypass the cell wall entirely (vancomycin, daptomycin, linezolid); carbapenemase-producing organisms → genotype determines which novel combination is active (KPC vs. NDM vs. OXA-48). The patient's culture and susceptibility data, interpreted through this framework, drive every definitive antibiotic decision.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 43–44: Antibacterial Agents	McGraw-Hill, 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapters 50–51: Antibacterial Agents	McGraw-Hill, 2023
Dresser GK, Spence JD, Bailey DG	Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition	Clin Pharmacokinet. 2000;38(1):41–57
FDA Drug Safety Communication	FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections	US Food and Drug Administration. 2016; updated 2018
Niemi M, Backman JT, Fromm MF, et al.	Pharmacokinetic interactions with rifampicin: clinical relevance	Clin Pharmacokinet. 2003;42(9):819–850
Lodise TP, Patel N, Lomaestro BM, et al.	Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients	Clin Infect Dis. 2009;49(4):507–514
Wagen AZ, Dagan R, Solt I, et al.	Serotonin syndrome associated with linezolid: a clinical review	J Antimicrob Chemother. 2016;71(3):566–571
Macy E, Romano A, Khan D	Practical management of antibiotic hypersensitivity in 2017	J Allergy Clin Immunol Pract. 2017;5(3):577–586
Rybak MJ, Le J, Lodise TP, et al.	Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review	Am J Health Syst Pharm. 2020;77(11):835–864
Rybak MJ, Le J, Lodise TP, et al.	Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review	Clin Infect Dis. 2020;71(6):1361–1364
Cunha BA	Minocycline and doxycycline: current and emerging clinical indications	Expert Rev Anti Infect Ther. 2012;10(6):731–742
Aronoff GR, Bennett WM, Berns JS, et al.	Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed.	Philadelphia: American College of Physicians; 2007
Verbeeck RK	Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction	Eur J Clin Pharmacol. 2008;64(12):1147–1161
Bookstaver PB, Bland CM, Griffin B, et al.	A review of antibiotic use in pregnancy	Pharmacotherapy. 2015;35(11):1052–1062
Hale TW	Medications and mothers milk	Planta Med. 2012;78(18):1837–1846
Smits A, Kulo A, de Hoon JN, Allegaert K	Pharmacokinetics of drugs in neonates: pattern recognition beyond single-drug studies	Curr Pharm Des. 2012;18(21):3119–3146
Gupta K, Hooton TM, Naber KG, et al.	International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update	Clin Infect Dis. 2011;52(5):e103–e120